Resveratrol: A focus on several neurodegenerative diseases

Oxidative Medicine and Cellular Longevity

Volumn 2015, Issue , 2015, Pages

  Tellone, Ester ^a   Galtieri, Antonio ^a   Russo, Annamaria ^a   Giardina, Bruno ^b,c   Ficarra, Silvana ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

RESVERATROL;

AMYOTROPHIC LATERAL SCLEROSIS; HUNTINGTON'S DISEASE; INTRINSIC PROPERTY; MOLECULAR TARGETS; MORPHOLOGICAL STRUCTURES; NEURODEGENERATIVE DISORDERS; NEURONAL CELL; PROTEIN TARGETS;

NEURODEGENERATIVE DISEASES;

GLUTAMIC ACID; RESVERATROL; STILBENE DERIVATIVE;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; DEGENERATIVE DISEASE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; HUMAN; HUNTINGTON CHOREA; NERVE CELL; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PROTEIN TARGETING; REVIEW; STRUCTURE ANALYSIS; TREATMENT RESPONSE; DRUG EFFECTS; METABOLISM; MITOCHONDRION; NEURODEGENERATIVE DISEASES; PATHOLOGY;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; HUMANS; HUNTINGTON DISEASE; MITOCHONDRIA; NEURODEGENERATIVE DISEASES; OXIDATIVE STRESS; PARKINSON DISEASE; STILBENES;

EID: 84935038697     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2015/392169     Document Type: Review

References (162)

1. L. Frémont, "Biological effects of resveratrol, " Life Sciences, vol. 66, no. 8, pp. 663-673, 2000.
2. F. Sparvoli, C. Martin, A. Scienza, G. Gavazzi, and C. Tonelli, "Cloning and molecular analysis of structural genes involved in flavonoid and stilbene biosynthesis in grape (Vitis vinifera L.), " Plant Molecular Biology, vol. 24, no. 5, pp. 743-755, 1994.
3. O. Choi, J. K. Lee, S.-Y. Kang et al., "Construction of artificial biosynthetic pathways for resveratrol glucoside derivatives, " Journal of Microbiology and Biotechnology, vol. 24, no. 5, pp. 614-618, 2014.
4. Q. Wang, J. Xu, G. E. Rottinghaus et al., "Resveratrol protects against global cerebral ischemic injury in gerbils, " Brain Research, vol. 958, no. 2, pp. 439-447, 2002.
5. T.Walle, F. Hsieh, M. H. DeLegge, J. E. Oatis Jr., and U. K. Walle, "High absorption but very low bioavailability of oral resveratrol in humans, "Drug Metabolism and Disposition, vol. 32, no. 12, pp. 1377-1382, 2004.
6. H. I. Rocha-González, M. Ambriz-Tututi, and V. Granados- Soto, "Resveratrol: A natural compound with pharmacological potential in neurodegenerative diseases, " CNS Neuroscience and Therapeutics, vol. 14, no. 3, pp. 234-247, 2008.
7. H. J. Forman, "Reactive oxygen species and α,β -unsaturated aldehydes as secondmessengers in signal transduction, " Annals of the New York Academy of Sciences, vol. 1203, pp. 35-44, 2010.
8. A.C.Andorn, R. S. Britton, and B.R. Bacon, "Evidence that lipid peroxidation and total iron are increased in Alzheimer's brain, " Neurobiology of Aging, vol. 11, pp. 316-320, 1990.
9. A.Granzotto and P. Zatta, "Resveratrol and Alzheimer's disease: message in a bottle on red wine and cognition, " Frontiers in Aging Neuroscience, vol. 6, article 95, 2014.
10. S. Boillée, C. Vande Velde, and D. Cleveland, "ALS: A disease of motor neurons and their nonneuronal neighbors, " Neuron, vol. 52, no. 1, pp. 39-59, 2006.
11. J. A. Duce and A. I. Bush, "Biological metals and Alzheimer's disease: implications for therapeutics and diagnostics, " Progress in Neurobiology, vol. 92, no. 1, pp. 1-18, 2010.
12. B. R. Roberts, T. M. Ryan, A. I. Bush, C. L. Masters, and J. A. Duce, "The role of metallobiology and amyloid-beta peptides in Alzheimer's disease, " Journal of Neurochemistry, vol. 120, no. 1, pp. 149-166, 2012.
13. R. González-Domínguez, T. García-Barrera, and J. L. Gómez- Ariza, "Characterization of metal profiles in serum during the progression of Alzheimer's disease, " Metallomics, vol. 6, no. 2, pp. 292-300, 2014.
14. A. R. LaSpada, "Finding a sirtuin truth inHuntington's disease, " Nature Medicine, vol. 18, no. 1, pp. 24-26, 2012.
15. J. Blesa, S. Phani, V. Jackson-Lewis, and S. Przedborski, "Classic and new animal models of Parkinson's disease, " Journal of Biomedicine and Biotechnology, vol. 2012, Article ID 845618, 10 pages, 2012.
16. L. I. Bruijn, T. M. Miller, and D.W. Cleveland, "Unraveling the mechanisms involved in motor neuron degeneration in ALS, " Annual Review of Neuroscience, vol. 27, pp. 723-749, 2004.
17. D. R. Rosen, T. Siddique, D. Patterson et al., "Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis, " Nature, vol. 362, no. 6415, pp. 59- 62, 1993.
18. A. Z. Herskovits and L. Guarente, "Sirtuin deacetylases in neurodegenerative diseases of aging, " Cell Research, vol. 23, no. 6, pp. 746-758, 2013.
19. J. M. C. Gutteridge, "Iron promoters of the Fenton reaction and lipid peroxidation can be released from haemoglobin by peroxides, " FEBS Letters, vol. 201, no. 2, pp. 291-295, 1986.
20. R. J. Castellani, R. K. Rolston, and M. A. Smith, "Alzheimer disease, " Disease-a-Month, vol. 56, no. 9, pp. 484-546, 2010.
21. W. G. Tatton, R. Chalmers-Redman, D. Brown, and N. Tatton, "Apoptosis in Parkinson's disease: signals for neuronal degradation, " Annals of Neurology, vol. 53, supplement 3, pp. S61-S72, 2003.
22. R. C. S. Seet, C.-Y. J. Lee, E. C. H. Lim et al., "Oxidative damage in Parkinson disease:measurement using accurate biomarkers, " Free Radical Biology and Medicine, vol. 48, no. 4, pp. 560-566, 2010.
23. S.Gandhi and A. Y. Abramov, "Mechanismof oxidative stress in neurodegeneration, " OxidativeMedicine and Cellular Longevity, vol. 2012, Article ID428010, 11 pages, 2012.
24. A. Cavallaro, T. Ainis, C. Bottari, and V. Fimiani, "Effect of resveratrol on some activities of isolated and in whole blood human neutrophils, " Physiological Research, vol. 52, no. 5, pp. 555-562, 2003.
25. M. A. Hussein, "A convenient mechanism for the free radical scavenging activity of resveratrol, " International Journal of Phytomedicine, vol. 3, no. 4, pp. 459-469, 2011.
26. C. Iuga, J. R. Alvarez-Idaboy, and N. Russo, "Antioxidant activity of trans-resveratrol toward hydroxyl and hydroperoxyl radicals: A quantum chemical and computational kinetics study, " Journal of Organic Chemistry, vol. 77, no. 8, pp. 3868-3877, 2012.
27. L. A. Stivala, M. Savio, F. Carafoli et al., "Specific structural determinants are responsible for the antioxidant activity and the cell cycle effects of resveratrol, " The Journal of Biological Chemistry, vol. 276, no. 25, pp. 22586-22594, 2001.
28. S. Petralia, C. Spatafora, C. Tringali, M. C. Foti, and S. Sortino, "Hydrogen atomabstraction fromresveratrol and two lipophilic derivatives by tert-butoxyl radicals. A laser flash photolysis study, " New Journal of Chemistry, vol. 28, no. 12, pp. 1484-1487, 2004.
29. J. Chao, M. S. Yu, Y. S. Ho, M. Wang, and R. C. C. Chang, "Dietary oxyresveratrol prevents parkinsonian mimetic 6- hydroxydopamine neurotoxicity, " Free Radical Biology and Medicine, vol. 45, no. 7, pp. 1019-1026, 2008.
30. S. Selvaraj, A. Mohan, S. Narayanan, S. Sethuraman, and U. M. Krishnan, "Dose-dependent interaction of trans-resveratrol with biomembranes: Effects on antioxidant property, " Journal of Medicinal Chemistry, vol. 56, no. 3, pp. 970-981, 2013.
31. E. Tellone, M. C. de Rosa, D. Pirolli et al., "Molecular interactions of hemoglobin with resveratrol: potential protective antioxidant role and metabolic adaptations of the erythrocyte, " Biological Chemistry, vol. 395, no. 3, pp. 347-354, 2014.
32. A. Galtieri, E. Tellone, S. Ficarra et al., "Resveratrol treatment induces redox stress in red blood cells:Apossible role of caspase 3 inmetabolismand anion transport, " Biological Chemistry, vol. 391, no. 9, pp. 1057-1065, 2010.
33. S. Pervaiz, "Resveratrol: from grapevines to mammalian biology, " The FASEB Journal, vol. 17, no. 14, pp. 1975-1985, 2003.
34. E.N. Frankel, A. L.Waterhouse, and J. E. Kinsella, "Inhibition of human LDL oxidation by resveratrol, " The Lancet, vol. 341, no. 8852, pp. 1103-1104, 1993.
35. G.-C. Yen, P.-D. Duh, and C.-W. Lin, "Effects of resveratrol and 4-hexylresorcinol on hydrogen peroxide-induced oxidative DNA damage in human lymphocytes, " Free Radical Research, vol. 37, no. 5, pp. 509-514, 2003.
36. C. A. de La Lastra and I. Villegas, "Resveratrol as an antioxidant and pro-oxidant agent: mechanisms and clinical implications, " Biochemical Society Transactions, vol. 35, no. 5, pp. 1156-1160, 2007.
37. S.-K. Tsai, L.-M.Hung, Y.-T. Fu et al., "Resveratrol neuroprotective effects during focal cerebral ischemia injury via nitric oxide mechanism in rats, " Journal of Vascular Surgery, vol. 46, no. 2, pp. 346-353, 2007.
38. C. Centeno-Baez, P. Dallaire, and A. Marette, "Resveratrol inhibition of inducible nitric oxide synthase in skeletal muscle involves AMPK but not SIRT1, " The American Journal of Physiology-Endocrinology and Metabolism, vol. 301, no. 5, pp. E922-E930, 2011.
39. T. C. Huang, K. T. Lu, Y. Y. P. Wo, Y. J. Wu, and Y. L. Yang, "Resveratrol protects rats from A-induced neurotoxicity by the reduction of iNOS expression and lipid peroxidation, " PLoS ONE, vol. 6, no. 12, Article ID e29102, 2011.
40. E. Savaskan, G. Olivieri, F. Meier, E. Seifritz, A. Wirz-Justice, and F. Muller-Spahn, "Red wine ingredient resveratrol protects from β-amyloid neurotoxicity, " Gerontology, vol. 49, no. 6, pp. 380-383, 2003.
41. V. Vingtdeux, U. Dreses-Werringloer, H. Zhao, P. Davies, and P. Marambaud, "Therapeutic potential of resveratrol in Alzheimer's disease, " BMC Neuroscience, vol. 9, supplement 2, article S6, 2008.
42. K. A. Ahmad, M.-V. Clement, and S. Pervaiz, "Pro-oxidant activity of lowdoses of resveratrol inhibits hydrogen peroxide- induced apoptosis, " Annals of the New York Academy of Sciences, vol. 1010, pp. 365-373, 2003.
43. A. Ahmad, F. A. Syed, S. Singh, and S. M. Hadi, "Prooxidant activity of resveratrol in the presence of copper ions:mutagenicity in plasmid DNA, " Toxicology Letters, vol. 159, no. 1, pp. 1-12, 2005.
44. I.Muqbil, F. W. J. Beck, B. Bao et al., "Old wine in a new bottle: The Warburg effect and anticancer mechanisms of resveratrol, " Current Pharmaceutical Design, vol. 18, no. 12, pp. 1645-1654, 2012.
45. J. K. Kundu and Y.-J. Surh, "Cancer chemopreventive and therapeutic potential of resveratrol: mechanistic perspectives, " Cancer Letters, vol. 269, no. 2, pp. 243-261, 2008.
46. Y. Bai, Q.-Q. Mao, J. Qin et al., "Resveratrol induces apoptosis and cell cycle arrest of human T24 bladder cancer cells in vitro and inhibits tumor growth in vivo, " Cancer Science, vol. 101, no. 2, pp. 488-493, 2010.
47. P.Parekh, L.Motiwale, N.Naik, and K.V.K.Rao, "Downregulation of cyclin D1 is associated with decreased levels of p38 MAP kinases, Akt/PKB and Pak1 during chemopreventive effects of resveratrol in liver cancer cells, " Experimental and Toxicologic Pathology, vol. 63, no. 1-2, pp. 167-173, 2011.
48. E. Fan, S. Jiang, L. Zhang, and Y. Bai, "Molecular mechanism of apoptosis induction by resveratrol, a natural cancer chemopreventive agent, " International Journal for Vitamin and Nutrition Research, vol. 78, no. 1, pp. 3-8, 2008.
49. E. Madan, S. Prasad, P. Roy, J. George, and Y. Shukla, "Regulation of apoptosis by resveratrol through JAK/STAT and mitochondria mediated pathway in human epidermoid carcinoma A431 cells, " Biochemical and Biophysical Research Communications, vol. 377, no. 4, pp. 1232-1237, 2008.
50. P. Roy, N. Kalra, S. Prasad, J.George, and Y. Shukla, "Chemopreventive potential of resveratrol in mouse skin tumors through regulation of mitochondrial and PI3K/AKT signaling pathways, " Pharmaceutical Research, vol. 26, no. 1, pp. 211-217, 2009.
51. M. Farnebo, V. J. N. Bykov, and K. G. Wiman, "The p53 tumor suppressor: A master regulator of diverse cellular processes and therapeutic target in cancer, " Biochemical and Biophysical Research Communications, vol. 396, no. 1, pp. 85-89, 2010.
52. M. Yánez, L. Galán, J. Matiás-Guiu, A. Vela, A. Guerrero, and A. G. García, "CSF from amyotrophic lateral sclerosis patients produces glutamate independent death of rat motor brain cortical neurons: protection by resveratrol but not riluzole, " Brain Research, vol. 1423, pp. 77-86, 2011.
53. F. Orallo, "Trans-resveratrol: A magical elixir of eternal youth?" Current Medicinal Chemistry, vol. 15, no. 19, pp. 1887-1898, 2008.
54. L. M. Vieira de Almeida, C. C. Pĩneiro, M. C. Leite et al., "Resveratrol increases glutamate uptake, glutathione content, and S100B secretion in cortical astrocyte cultures, " Cellular and Molecular Neurobiology, vol. 27, no. 5, pp. 661-668, 2007.
55. F. Simao, A. Matte, A. S. Pagnussat, C. A. Netto, and C. G. Salbego, "Resveratrol prevents CA1 neurons against ischemic injury by parallel modulation of both GSK-3β and CREB through PI3-K/Akt pathways, " European Journal of Neuroscience, vol. 36, no. 7, pp. 2899-2905, 2012.
56. T. D. King, B. Clodfelder-Miller, K. A. Barksdale, and G. N. Bijur, "Unregulated mitochondrial GSK3β activity results in NADH: ubiquinone oxidoreductase deficiency, " Neurotoxicity Research, vol. 14, no. 4, pp. 367-382, 2008.
57. D.-W. Li, Z.-Q. Liu, W. Chen, M. Yao, and G.-R. Li, "Association of glycogen synthase kinase-3β with Parkinson's disease (Review), " Molecular Medicine Reports, vol. 9, no. 6, pp. 2043- 2050, 2014.
58. A. V. Witte, L. Kerti, D. S. Margulies, and A. Floel, "Effects of resveratrol on memory performance, hippocampal functional connectivity, and glucose metabolism in healthy older adults, " Journal of Neuroscience, vol. 34, no. 23, pp. 7862-7870, 2014.
59. D. O. Kennedy, E. L. Wightman, J. L. Reay et al., "Effects of resveratrol on cerebral blood flow variables and cognitive performance in humans: A double-blind, placebo-controlled, crossover investigation, " American Journal of Clinical Nutrition, vol. 91, no. 6, pp. 1590-1597, 2010.
60. E. L. Wightman, J. L. Reay, C. F. Haskell, G. Williamson, T. P. Dew, and D. O. Kennedy, "Effects of resveratrol alone or in combination with piperine on cerebral blood flow parameters and cognitive performance in human subjects: A randomised, double-blind, placebo-controlled, cross-over investigation, " British Journal of Nutrition, vol. 112, no. 2, pp. 203-213, 2014.
61. F. Uchiumi, T. Watanabe, S. Hasegawa, T. Hoshi, Y. Higami, and S.-I. Tanuma, "The effect of resveratrol on the Werner syndrome RecQ helicase gene and telomerase activity, " Current Aging Science, vol. 4, no. 1, pp. 1-7, 2011.
62. T. Jayasena, A. Poljak, G. Smythe, N. Braidy, G. Munch, and P. Sachdev, "The role of polyphenols in the modulation of sirtuins and other pathways involved in Alzheimer's disease, " Ageing Research Reviews, vol. 12, no. 4, pp. 867-883, 2013.
63. E. Sahin, S.Colla, M. Liesa et al., "Telomere dysfunction induces metabolic and mitochondrial compromise, " Nature, vol. 470, no. 7334, pp. 359-365, 2011.
64. Z. Wu, P. Puigserver, U. Andersson et al., "Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1, " Cell, vol. 98, no. 1, pp. 115-124, 1999.
65. R. C. Scarpulla, "Metabolic control ofmitochondrial biogenesis through the PGC-1 family regulatory network, " Biochimica et Biophysica Acta-Molecular Cell Research, vol. 1813, no. 7, pp. 1269-1278, 2011.
66. X. Mu, G. He, Y. Cheng, X. Li, B. Xu, and G. Du, "Baicalein exerts neuroprotective effects in 6-hydroxydopamine-induced experimental parkinsonism in vivo and in vitro, " Pharmacology Biochemistry and Behavior, vol. 92, no. 4, pp. 642-648, 2009.
67. Y. Wu, X. Li, J. X. Zhu et al., "Resveratrol-activated AMPK/SIRT1/autophagy in cellular models of Parkinson's disease, " NeuroSignals, vol. 19, no. 3, pp. 163-174, 2011.
68. Z. Li, L. Pang, F. Fang et al., "Resveratrol attenuates brain damage in a rat model of focal cerebral ischemia via upregulation of hippocampal Bcl-2, " Brain Research, vol. 1450, pp. 116-124, 2012.
69. M. Kairisalo, A. Bonomo, A. Hyrskyluoto et al., "Resveratrol reduces oxidative stress and cell death and increases mitochondrial antioxidants and XIAP in PC6.3-cells, " Neuroscience Letters, vol. 488, no. 3, pp. 263-266, 2011.
70. F. Jin, Q. Wu, Y.-F. Lu, Q.-H. Gong, and J.-S. Shi, "Neuroprotective effect of resveratrol on 6-OHDA-induced Parkinson's disease in rats, " European Journal of Pharmacology, vol. 600, no. 1-3, pp. 78-82, 2008.
71. F. Zhang, J.-S. Shi, H. Zhou, B. Wilson, J.-S. Hong, and H.-M. Gao, "Resveratrol protects dopamine neurons against lipopolysaccharide-induced neurotoxicity through its anti inflammatory actions, " Molecular Pharmacology, vol. 78, no. 3, pp. 466-477, 2010.
72. D. J. Selkoe, "Alzheimer's disease is a synaptic failure, " Science, vol. 298, no. 5594, pp. 789-791, 2002.
73. R. E. Tanzi, "The synaptic Aβ hypothesis of Alzheimer disease, " Nature Neuroscience, vol. 8, no. 8, pp. 977-979, 2005.
74. L. Saragoni, P. Hernández, and R. B. Maccioni, "Differential association of tau with subsets of microtubules containing posttranslationally-modified tubulin variants in neuroblastoma cells, " Neurochemical Research, vol. 25, no. 1, pp. 59-70, 2000.
75. M. J. Smith, R. A. Crowther, and M. Goedert, "The natural osmolyte trimethylamine N-oxide (TMAO) restores the ability of mutant tau to promote microtubule assembly, " FEBS Letters, vol. 484, no. 3, pp. 265-270, 2000.
76. A. Takashima, T. Honda, K. Yasutake et al., "Activation of tau protein kinase I/glycogen synthase kinase-3β by amyloid β peptide (25-35) enhances phosphorylation of tau in hippocampal neurons, " Neuroscience Research, vol. 31, no. 4, pp. 317-323, 1998.
77. A. C. Cuello, "Intracellular and extracellular Aβ, a tale of two neuropathologies, " Brain Pathology, vol. 15, no. 1, pp. 66-71, 2005.
78. D. W. Ethell and L. A. Buhler, "Fas ligand-mediated apoptosis in degenerative disorders of the brain, " Journal of Clinical Immunology, vol. 23, no. 6, pp. 439-446, 2003.
79. H. Dudek, S. R.Datta, T. F. Franke et al., "Regulation of neuronal survival by the serine-threonine protein kinase Akt, " Science, vol. 275, no. 5300, pp. 661-665, 1997.
80. Y. Feng, X.-P.Wang, S.-G. Yang et al., "Resveratrol inhibits betaamyloid oligomeric cytotoxicity but does not prevent oligomer formation, " NeuroToxicology, vol. 30, no. 6, pp. 986-995, 2009.
81. Y. Porat, A. Abramowitz, and E. Gazit, "Inhibition of amyloid fibril formation by polyphenols: structural similarity and aromatic interactions as a common inhibition mechanism, " Chemical Biology and Drug Design, vol. 67, no. 1, pp. 27-37, 2006.
82. M. Gertz, G. T. T. Nguyen, F. Fischer et al., "A molecular mechanism for direct sirtuin activation by resveratrol, " PLoS ONE, vol. 7, no. 11, Article ID e49761, 2012.
83. B. P. Hubbard, A. P. Gomes, H. Dai et al., "Evidence for a common mechanism of SIRT1 regulation by allosteric activators, " Science, vol. 339, no. 6124, pp. 1216-1219, 2013.
84. W. Qin, T. Yang, L. Ho et al., "Neuronal SIRT1 activation as a novel mechanism underlying the prevention of alzheimer disease amyloid neuropathology by calorie restriction, " The Journal of Biological Chemistry, vol. 281, no. 31, pp. 21745-21754, 2006.
85. Y. Zhou, Y. Su, B. Li et al., "Non-steroidal anti-inflammatory drugs can lower amyloidogenic Ab42 by inhibiting Rho, " Science, vol. 302, pp. 1215-1217, 2003.
86. T. J. Cohen, J. L. Guo, D. E. Hurtado et al., "The acetylation of tau inhibits its function and promotes pathological tau aggregation, " Nature Communications, vol. 2, no. 1, article 252, 2011.
87. S.-W.Min, S.-H. Cho, Y. Zhou et al., "Acetylation of tau inhibits its degradation and contributes to tauopathy, " Neuron, vol. 67, no. 6, pp. 953-966, 2010.
88. C. Hooper, E. Meimaridou, M. Tavassoli, G. Melino, S. Lovestone, and R. Killick, "p53 is upregulated in Alzheimer's disease and induces tau phosphorylation in HEK293a cells, " Neuroscience Letters, vol. 418, no. 1, pp. 34-37, 2007.
89. C. Cantó and J. Auwerx, "Targeting sirtuin 1 to improve metabolism: All you need is NAD+?" Pharmacological Reviews, vol. 64, no. 1, pp. 166-187, 2012.
90. V. Vingtdeux, L. Giliberto, H. Zhao et al., "AMP-activated protein kinase signaling activation by resveratrol modulates amyloid-beta peptide metabolism, " The Journal of Biological Chemistry, vol. 285, no. 12, pp. 9100-9113, 2010.
91. 2+ and AMP, " Biochemical Journal, vol. 426, no. 1, pp. 109-118, 2010.
92. S.-J. Park, F. Ahmad, A. Philp et al., "Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases, " Cell, vol. 148, supplement 3, pp. 421-433, 2012.
93. S. A. Hawley, F. A. Ross, C. Chevtzoff et al., "Use of cells expressing γ subunit variants to identify diverse mechanisms of AMPK activation, " Cell Metabolism, vol. 11, no. 6, pp. 554-565, 2010.
94. C. Canto and J. Auwerx, "AMP-activated protein kinase and its downstream transcriptional pathways, " Cellular and Molecular Life Sciences, vol. 67, no. 20, pp. 3407-3423, 2010.
95. X. Wang, W. Wang, L. Li, G. Perry, H. G. Lee, and X. Zhu, "Oxidative stress andmithocondrial dysfunction inAlzheimer's disease, " Biochimica et Biophysica Acta, vol. 1842, no. 8, pp. 1240-1247, 2014.
96. K.Higashida, S.H.Kim, S.R. Jung, M. Asaka, J.O.Holloszy, and D.-H.Han, "Effects of resveratrol and SIRT1 on PGC-1α activity and mitochondrial biogenesis: A reevaluation, " PLoS Biology, vol. 11, no. 7, Article ID e1001603, 2013.
97. A. P. Gomes, N. L. Price, A. J. Y. Ling et al., "Declining NAD+ induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging, " Cell, vol. 155, no. 7, pp. 1624-1638, 2013.
98. C. López-Otín, M. A. Blasco, L. Partridge, M. Serrano, and G. Kroemer, "The hallmarks of aging, " Cell, vol. 153, no. 6, pp. 1194- 1217, 2013.
99. J. P. G. Vonsattel and M. Di Figlia, "Huntington disease, " Journal of Neuropathology and Experimental Neurology, vol. 57, no. 5, pp. 369-384, 1998.
100. M. E. MacDonald, C. M. Ambrose, M. P. Duyao et al., "A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes.The Huntington's Disease Collaborative Research Group, " Cell, vol. 72, no. 6, pp. 971-983, 1993.
101. P. Lajoie and E. L. Snapp, "Formation and toxicity of soluble polyglutamine oligomers in living cells, " PLoS ONE, vol. 5, no. 12, Article ID e15245, 2010.
102. G. Cisbani and F. Cicchetti, "An in vitro perspective on the molecular mechanisms underlying mutant huntingtin protein toxicity, " Cell Death and Disease, vol. 3, no. 8, article e380, 2012.
103. P. Kumar, S. S. V. Padi, P. S. Naidu, and A. Kumar, "Cyclooxygenase inhibition attenuates 3-nitropropionic acid-induced neurotoxicity in rats: possible antioxidant mechanisms, " Fundamental and Clinical Pharmacology, vol. 21, no. 3, pp. 297-306, 2007.
104. X. Feng, N. Liang, D. Zhu et al., "Resveratrol inhibits β-amyloid- induced neuronal apoptosis through regulation of SIRT1- ROCK1 signaling pathway, " PLoS ONE, vol. 8, no. 3, Article ID e59888, 2013.
105. B.-I. Bae, H. Xu, S. Igarashi et al., "p53 mediates cellular dysfunction and behavioral abnormalities inHuntington's disease, " Neuron, vol. 47, no. 1, pp. 29-41, 2005.
106. J. Luo, A. Y. Nikolaev, S.-I. Imai et al., "Negative control of p53 by Sir2α promotes cell survival under stress, " Cell, vol. 107, no. 2, pp. 137-148, 2001.
107. H. Vaziri, S. K. Dessain, E. N. Eaton et al., "hSIR2SIRT1 functions as an NAD-dependent p53 deacetylase, " Cell, vol. 107, no. 2, pp. 149-159, 2001.
108. S. Zhou, S. Kachhap, and K. K. Singh, "Mitochondrial impairment in p53-deficient human cancer cells, " Mutagenesis, vol. 18, no. 3, pp. 287-292, 2003.
109. S. Matoba, J.-G. Kang, W. D. Patino et al., "p53 regulates mitochondrial respiration, " Science, vol. 312, no. 5780, pp. 1650- 1653, 2006.
110. A. Granzotto, S. Bolognin, J. Scancar, R. Milacic, and P. Zatta, " β-amyloid toxicity increases with hydrophobicity in the presence of metal ions, " Monatshefte fur Chemie, vol. 142, no. 4, pp. 421-430, 2011.
111. K. M. Choi, H. L. Lee, Y. Y. Kwon, M. S. Kang, S. K. Lee, and C. K. Lee, "Enhancement of mitochondrial function correlates with the extension of lifespan by caloric restriction and caloric restriction mimetics in yeast, " Biochemical and Biophysical Research Communications, vol. 441, no. 1, pp. 236-242, 2013.
112. V. Desquiret-Dumas, N. Gueguen, G. Leman et al., "Resveratrol induces amitochondrial complex i-dependent increase in nadh oxidation responsible for sirtuin activation in liver cells, " The Journal of Biological Chemistry, vol. 288, no. 51, pp. 36662- 36675, 2013.
113. D. Lettieri Barbato, S. Baldelli, B. Pagliei, K. Aquilano, and M. R. Ciriolo, "Caloric restriction and the nutrient-sensing PGC-1α in mitochondrial homeostasis: new perspectives in neurodegeneration, " International Journal of Cell Biology, vol. 2012, Article ID759583, 11 pages, 2012.
114. M. C. De Rijk, C. Tzourio, M. M. B. Breteler et al., "Prevalence of parkinsonism and Parkinson's disease in Europe: The EUROPARKINSONcollaborative study. EuropeanCommunity Concerted Action on the Epidemiology of Parkinson's disease, " Journal of Neurology Neurosurgery and Psychiatry, vol. 62, no. 1, pp. 10-15, 1997.
115. T. Gasser, "Genetics of Parkinson's disease, " Current Opinion in Neurology, vol. 18, pp. 363-369, 2005.
116. Y. He, T. Lee, and S. K. Leong, "6-Hydroxydopamine induced apoptosis of dopaminergic cells in the rat substantia nigra, " Brain Research, vol. 858, no. 1, pp. 163-166, 2000.
117. B. I. Giasson, H. Ischiropoulos, V. M.-Y. Lee, and J. Q. Trojanowski, "The relationship between oxidative/nitrative stress and pathological inclusions in Alzheimer's and Parkinson's diseases, " Free Radical Biology and Medicine, vol. 32, no. 12, pp. 1264-1275, 2002.
118. D.Alvira, M. Yeste-Velasco, J. Folch et al., "Comparative analysis of the effects of resveratrol in two apoptotic models: inhibition of complex I and potassium deprivation in cerebellar neurons, " Neuroscience, vol. 147, no. 3, pp. 746-756, 2007.
119. A. Ferretta, A. Gaballo, P. Tanzarella et al., "Effect of resveratrol on mitochondrial function: implications in parkin-associated familiar Parkinson's disease, " Biochimica et Biophysica Acta- Molecular Basis of Disease, vol. 1842, no. 7, pp. 902-915, 2014.
120. 2+ signaling in astrocytes through reactive oxygen species generated by monoamine oxidase, " Journal of Biological Chemistry, vol. 285, no. 32, pp. 25018-25023, 2010.
121. D. J. Surmeier, J. N. Guzman, J. Sanchez-Padilla, and J. A. Goldberg, "The origins of oxidant stress in Parkinson's disease and therapeutic strategies, " Antioxidants and Redox Signaling, vol. 14, no. 7, pp. 1289-1301, 2011.
122. R. S. Duncan, D. L. Goad, M. A. Grillo, S. Kaja, A. J. Payne, and P. Koulen, "Control of intracellular calcium signaling as a neuroprotective strategy, "Molecules, vol. 15, no. 3, pp. 1168-1195, 2010.
123. A. E. McCalley, S.Kaja, A. J. Payne, and P.Koulen, "Resveratrol and calcium signaling: molecular mechanisms and clinical relevance, " Molecules, vol. 19, no. 6, pp. 7327-7340, 2014.
124. J. Blanchet, F. Longpré, G. Bureau et al., "Resveratrol, a red wine polyphenol, protects dopaminergic neurons in MPTP-treated mice, " Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 32, no. 5, pp. 1243-1250, 2008.
125. G. Donmez, A. Arun, C. Y. Chung, P. J. Mclean, S. Lindquist, and L.Guarente, "SIRT1 protects against alpha-synuclein aggregation by activating molecular chaperones, " The Journal of Neuroscience, vol. 32, no. 1, pp. 124-132, 2012.
126. R. Raynes, B. D. Leckey Jr., K. Nguyen, and S. D. Westerheide, "Heat shock and caloric restriction have a synergistic effect on the heat shock response in a sir2.1-dependent manner in Caenorhabditis elegans, "The Journal of Biological Chemistry, vol. 287, no. 34, pp. 29045-29053, 2012.
127. S. D. Westerheide, J. Anckar, S.M. Stevens Jr., L. Sistonen, and R. I.Morimoto, "Stress-inducible regulation of heat shock factor 1 by the deacetylase SIRT, " Science, vol. 323, no. 5917, pp. 1063- 1066, 2009.
128. D.-W. Li, Z.-Q. Liu, W. Chen, M. Yao, and G.-R. Li, "Association of glycogen synthase kinase-3β with Parkinson's disease (Review), " Molecular Medicine Reports, vol. 9, no. 6, pp. 2043- 2050, 2014.
129. F. Simao, A. Matté, A. S. Pagnussat, C. A. Netto, and C. G. Salbego, "Resveratrol prevents CA1 neurons against ischemic injury by parallel modulation of both GSK-3β and CREB through PI3-K/Akt pathways, " European Journal of Neuroscience, vol. 36, no. 7, pp. 2899-2905, 2012.
130. L. P. Rowland and N. A. Shneider, "Amyotrophic lateral sclerosis, " The New England Journal of Medicine, vol. 344, no. 22, pp. 1688-1700, 2001.
131. D. W. Mulder, L. T. Kurland, K. P. Offord, and M. Beard, "Familial adult motor neuron disease: Amyotrophic lateral sclerosis, " Neurology, vol. 36, no. 4, pp. 511-517, 1986.
132. S. Da Cruz and D. W. Cleveland, "Understanding the role of TDP-43 and FUS/TLS in ALS and beyond, " Current Opinion in Neurobiology, vol. 21, no. 6, pp. 904-919, 2011.
133. M. Prudencio, P. J. Hart, D. R. Borchelt, and P. M. Andersen, "Variation in aggregation propensities among ALS-associated variants of SOD1: correlation to human disease, " Human Molecular Genetics, vol. 18, no. 17, pp. 3217-3226, 2009.
134. M. DeJesus-Hernandez, I. R. Mackenzie, B. F. Boeve et al., "Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS, " Neuron, vol. 72, no. 2, pp. 245-256, 2011.
135. A. E. Renton, E. Majounie, A. Waite et al., "A hexanucleotide repeat expansion inC9ORF72 is the causeof chromosome9p21- linked ALS-FTD, " Neuron, vol. 72, no. 2, pp. 257-268, 2011.
136. J. D. Rothstein, "Current hypotheses for the underlying biology of amyotrophic lateral sclerosis, " Annals of Neurology, vol. 65, no. 1, pp. S3-S9, 2009.
137. C. M. Karch, M. Prudencio, D. D. Winkler, P. J. Hart, and D. R. Borchelt, "Role of mutant SOD1 disulfide oxidation and aggregation in the pathogenesis of familial ALS, " Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 19, pp. 7774-7779, 2009.
138. J. Dunlop, H. Beal McIlvain, Y. She, and D. S. Howland, "Impaired spinal cord glutamate transport capacity and reduced sensitivity to riluzole in a transgenic superoxide dismutase mutant rat model of amyotrophic lateral sclerosis, " Journal of Neuroscience, vol. 23, no. 5, pp. 1688-1696, 2003.
139. F. J. Miana-Mena, E. Piedrafita, C. González-Mingot et al., "Levels of membrane fluidity in the spinal cord and the brain in an animal model of amyotrophic lateral sclerosis, " Journal of Bioenergetics and Biomembranes, vol. 43, no. 2, pp. 181-186, 2011.
140. P. Shi, J. Gal, D. M. Kwinter, X. Liu, and H.Zhu, "Mitochondrial dysfunction in amyotrophic lateral sclerosis, " Biochimica et Biophysica Acta, vol. 1802, no. 1, pp. 45-51, 2010.
141. M. Cozzolino and M. T. Carrì, "Mitochondrial dysfunction in ALS, " Progress in Neurobiology, vol. 97, no. 2, pp. 54-66, 2012.
142. L. Faes and G. Callewaert, "Mitochondrial dysfunction in familial amyotrophic lateral sclerosis, " Journal of Bioenergetics and Biomembranes, vol. 43, no. 6, pp. 587-592, 2011.
143. A. Kumar, D. Ghosh, and R. L. Singh, "Amyotrophic lateral sclerosis and metabolomics: clinical implication and therapeutic approach, " Journal of Biomarkers, vol. 2013, Article ID 538765, 15 pages, 2013.
144. P. Pasinelli and R.H. Brown, "Molecular biologyof amyotrophic lateral sclerosis: insights from genetics, " Nature Reviews Neuroscience, vol. 7, no. 9, pp. 710-723, 2006.
145. M. T. Carrì and M. Cozzolino, "SOD1 and mitochondria in ALS: A dangerous liaison, " Journal of Bioenergetics and Biomembranes, vol. 43, no. 6, pp. 593-599, 2011.
146. A. Igoudjil, J. Magrané, L. R. Fischer et al., "In vivo pathogenic role of mutant SOD1 localized in the mitochondrial intermembrane space, " Journal of Neuroscience, vol. 31, no. 44, pp. 15826- 15837, 2011.
147. R. A. Saccon, R. K. A. Bunton-Stasyshyn, E.M. C. Fisher, and P. Fratta, "Is SOD1 loss of function involved in amyotrophic lateral sclerosis?" Brain, vol. 136, no. 8, pp. 2342-2358, 2013.
148. M. K. Jaiswal, "Selective vulnerability of motoneuron and perturbed mitochondrial calcium homeostasis in amyotrophic lateral sclerosis: implications for motoneurons specific calcium dysregulation, " Molecular and Cellular Therapies, vol. 2, no. 1, article 26, 2014.
149. J. Lautenschlager, T. Prell, J. Ruhmer, L. Weidemann, O. W. Witte, and J. Grosskreutz, "Overexpression of human mutated G93A SOD1 changes dynamics of the ER mitochondria calcium cycle specifically in mouse embryonic motor neurons, " Experimental Neurology, vol. 247, pp. 91-100, 2013.
150. S. D. Rao and J. H.Weiss, "Excitotoxic and oxidative cross-talk between motor neurons and glia in ALS pathogenesis, " Trends in Neurosciences, vol. 27, no. 1, pp. 17-23, 2004.
151. C. Raoul, A. G. Estévez, H. Nishimune et al., "Motoneuron death triggered by a specific pathway downstream of fas: potentiation by ALS-linked SOD1 mutations, " Neuron, vol. 35, no. 6, pp. 1067-1083, 2002.
152. H. Kawamata, S. K. Ng, N. Diaz et al., "Abnormal intracellular calcium signaling and SNARE dependent exocytosis contributes to SOD1G93A astrocyte- mediated toxicity in amyotrophic lateral sclerosis, " The Journal of Neuroscience, vol. 34, no. 6, pp. 2331-2348, 2014.
153. M. L. Tradewell, Z. Yu, M. Tibshirani, M.-C. Boulanger, H. D. Durham, and S. Richard, "Arginine methylation by prmt1 regulates nuclear-cytoplasmic localization and toxicity of FUS/TLS harbouring ALS-linkedmutations, " Human Molecular Genetics, vol. 21, no. 1, Article ID ddr448, pp. 136-149, 2012.
154. L. Song, L. Chen, X. Zhang, J. Li, and W. Le, "Resveratrol ameliorates motor neuron degeneration and improves survival in SOD1G93A mouse model of amyotrophic lateral sclerosis, " BioMed Research International, vol. 2014, Article ID 483501, 10 pages, 2014.
155. S.Davinelli, N. Sapere, M.Visentin, D. Zella, and G. Scapagnini, "Enhancement of mitochondrial biogenesis with polyphenols: combined effects of resveratrol and equol in human endothelial cells, " Immunity & Ageing, vol. 10, no. 1, article 28, 2013.
156. W. Zhao, M. Varghese, S. Yemul et al., "Peroxisome proliferator activator receptor gamma coactivator-1alpha (PGC-1α) improves motor performance and survival in a mouse model of amyotrophic lateral sclerosis, " Molecular Neurodegeneration, vol. 6, no. 1, article 51, 2011.
157. S. M.Han, H. Tsuda, Y. Yang et al., "Secreted VAPB/ALS8major sperm protein domains modulate mitochondrial localization and morphology via growth cone guidance receptors, " Developmental Cell, vol. 22, no. 2, pp. 348-362, 2012.
158. G. Donmez, A. Arun, C.-Y. Chung, P. J. Mclean, S. Lindquist, and L. Guarente, "SIRT1 protects against α-synuclein aggregation by activating molecular chaperones, " Journal of Neuroscience, vol. 32, no. 1, pp. 124-132, 2012.
159. D. Kim, M. D. Nguyen, M.M. Dobbin et al., "SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis, " The EMBO Journal, vol. 26, no. 13, pp. 3169-3179, 2007.
160. T.Walle, "Bioavailability of resveratrol, " Annals of the New York Academy of Sciences, vol. 1215, no. 1, pp. 9-15, 2011.
161. A. Scala, S. Ficarra, A. Russo et al., "A new erythrocyte-based biochemical approach to predict the antiproliferative effects of heterocyclic scaffolds: The case of indolone, " Biochimica et Biophysica Acta-General Subjects, vol. 1850, no. 1, pp. 73-79, 2015.
162. D. Su, Y. Cheng, M. Liu et al., "Comparision of piceid and resveratrol in antioxidation and antiproliferation activities in vitro, " PLoS ONE, vol. 8, no. 1, Article ID e54505, 2013.